Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Pamela Blair Allen & Leo I. Gordon. (2016) PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher. Expert Review of Hematology 9:10, pages 939-949.
Read now
Read now
Sam Mayes, Adam Gibb & Tim Illidge. (2012) Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 99-107.
Read now
Read now
Donatella Aldinucci, Annunziata Gloghini, Antonio Pinto, Alfonso Colombatti & Antonino Carbone. (2012) The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leukemia & Lymphoma 53:2, pages 195-201.
Read now
Read now
Lauren S. Maeda, Mark Lee & Ranjana H Advani. (2011) Current concepts and controversies in the management of early stage Hodgkin lymphoma. Leukemia & Lymphoma 52:6, pages 962-971.
Read now
Read now
Randy D. Gascoyne, Andreas Rosenwald, Sibrand Poppema & Georg Lenz. (2010) Prognostic biomarkers in malignant lymphomas. Leukemia & Lymphoma 51:sup1, pages 11-19.
Read now
Read now
Denize Azambuja, Izidore S. Lossos, Irene Biasoli, José Carlos Morais, Luciana Britto, Adriana Scheliga, Wolmar Pulcheri, Yasodha Natkunam & Nelson Spector. (2009) Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. Leukemia & Lymphoma 50:11, pages 1830-1836.
Read now
Read now
Articles from other publishers (29)
Anqi Liang, Ying Kong, Zhihong Chen, Yishu Qiu, Yanhong Wu, Xiao Zhu & Zesong Li. (2024) Advancements and applications of single-cell multi-omics techniques in cancer research: Unveiling heterogeneity and paving the way for precision therapeutics. Biochemistry and Biophysics Reports 37, pages 101589.
Crossref
Crossref
Tianyu Yang, Shuang Liu, Rui Zuo, Hongwei Liang, Lu Xu, Zhengjie Wang, Xiaoliang Chen & Hua Pang. (2023) Prognostic role of pretreatment 18F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study. BMC Medical Imaging 23:1.
Crossref
Crossref
Rafael Dezen Gaiolla, Marcelo Padovani de Toledo Moraes & Deilson Elgui de Oliveira. (2021) SNPs in genes encoding for IL-10, TNF-α, and NFκB p105/p50 are associated with clinical prognostic factors for patients with Hodgkin lymphoma. PLOS ONE 16:3, pages e0248259.
Crossref
Crossref
Catherine S Diefenbach, Fangxin Hong, Richard F Ambinder, Jonathon B Cohen, Michael J Robertson, Kevin A David, Ranjana H Advani, Timothy S Fenske, Stefan K Barta, Neil D Palmisiano, Jakub Svoboda, David S Morgan, Reem Karmali, Elad Sharon, Howard Streicher, Brad S Kahl & Stephen M Ansell. (2020) Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. The Lancet Haematology 7:9, pages e660-e670.
Crossref
Crossref
Francisco Mestre, Antonio Gutiérrez, Jose Rodriguez, Rafael Ramos, Juan Fernando Garcia, Jordi Martinez-Serra, Marta Casasus, Cristina Nicolau, Leyre Bento, Ines Herraez, Paloma Lopez-Perezagua, Jaime Daumal & Joan Besalduch. (2015) Radiation Therapy Overcomes Adverse Prognostic Role of Cyclooxygenase-2 Expression on Reed-Sternberg Cells in Early Hodgkin Lymphoma. International Journal of Radiation Oncology*Biology*Physics 92:1, pages 84-90.
Crossref
Crossref
Catherine Diefenbach & Ranjana Advani. (2014) Customized Targeted Therapy in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 105-122.
Crossref
Crossref
Rebecca L. King, Matthew T. Howard & Adam Bagg. (2014) Hodgkin Lymphoma. Advances in Anatomic Pathology 21:1, pages 12-25.
Crossref
Crossref
Adam Jona, Peter Szodoray & Arpad Illés. (2013) Immunologic pathomechanism of Hodgkin's lymphoma. Experimental Hematology 41:12, pages 995-1004.
Crossref
Crossref
Hervé Ghesquières, Matthew J. Maurer, Olivier Casasnovas, Stephen M. Ansell, Beth R. Larrabee, Eva Lech-Maranda, Anne J. Novak, Anne-Laure Borrel, Susan L. Slager, Pauline Brice, Cristine Allmer, Annie Brion, Steven C. Ziesmer, Franck Morschhauser, Thomas M. Habermann, Isabelle Gaillard, Brian K. Link, Aspasia Stamatoullas, Christophe Fermé, Ahmet Dogan, William R. Macon, Josée Audouin, James R. Cerhan & Gilles Salles. (2013) Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. Cytokine 64:2, pages 523-531.
Crossref
Crossref
Catherine Diefenbach & Christian Steidl. (2013) New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clinical Cancer Research 19:11, pages 2797-2803.
Crossref
Crossref
Alfons Navarro, Carmen Muñoz, Anna Gaya, Marina Díaz-Beyá, Bernat Gel, Rut Tejero, Tania Díaz, Antonio Martinez & Mariano Monzó. (2013) MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients. PLoS ONE 8:5, pages e64716.
Crossref
Crossref
Jing OuyangAnnette Plütschow, Elke Pogge von StrandmannKatrin S. ReinersSabine Ponader, Gabriel A. Rabinovich, Donna Neuberg, Andreas Engert & Margaret A. Shipp. (2013) Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 121:17, pages 3431-3433.
Crossref
Crossref
Magdy BedewyShereen El-MaghrabyAhmed Bedewy. (2013) CD163 and c-Met expression in the lymph node and the correlations between elevated levels of serum free light chain and the different clinicopathological parameters of advanced classical Hodgkin's lymphoma. Blood Research 48:2, pages 121.
Crossref
Crossref
Theodoros P. Vassilakopoulos & Maria K. Angelopoulou. (2013) Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years. Seminars in Hematology 50:1, pages 4-14.
Crossref
Crossref
Wesley Greaves, Lianchun Xiao, Beatriz Sanchez-Espiridion, Kranthi Kunkalla, Kunal S Dave, Cynthia S Liang, Rajesh R Singh, Anas Younes, L Jeffrey Medeiros & Francisco Vega. (2012) Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. Journal of Hematology & Oncology 5:1.
Crossref
Crossref
Ingrid Glimelius, Fredrik Qvarnström, Martin Simonsson, Anders Ekwall, Karin E Smedby, Daniel Molin & Rose-Marie Amini. (2012) Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma. Histopathology 61:1, pages 26-32.
Crossref
Crossref
Francisco MestreAntonio Gutierrez, Rafael RamosJordi Martinez-Serra, Lydia SánchezGabriel Matheu, Teresa Ros, Juan Fernando GarciaJose Rodriguez. (2012) Expression of COX-2 on Reed-Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood 119:25, pages 6072-6079.
Crossref
Crossref
D. Azambuja, Y. Natkunam, I. Biasoli, I.S. Lossos, M.W. Anderson, J.C. Morais & N. Spector. (2012) Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Annals of Oncology 23:3, pages 736-742.
Crossref
Crossref
Ingrid Glimelius, Jenny Rubin, Klaus Rostgaard, Rose-Marie Amini, Martin Simonsson, Karina M. Sorensen, Karin E. Smedby, Per Venge, Henrik Hjalgrim, Daniel Molin & Gunilla Enblad. (2011) Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin’s Lymphoma - a population-based study. European Journal of Haematology 87:3, pages 208-216.
Crossref
Crossref
Shouying Du, Richard Scuderi, Denise M. Malicki, Jennifer Willert, John Bastian & Noel Weidner. (2012) Hodgkin's and Non-Hodgkin's Lymphomas Occurring in Two Brothers with Wiskott-Aldrich Syndrome and Review of the Literature. Pediatric and Developmental Pathology 14:1, pages 64-70.
Crossref
Crossref
Yvette L. Kasamon. (2011) Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography. Advances in Hematology 2011, pages 1-12.
Crossref
Crossref
S. Montes-Moreno. (2011) Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment. Advances in Hematology 2011, pages 1-6.
Crossref
Crossref
Falko Fend. 2011. Hematopathology. Hematopathology
454
472
.
Kristie A. Blum. (2010) Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma. Hematology 2010:1, pages 93-100.
Crossref
Crossref
Donatella Aldinucci, Annunziata Gloghini, Antonio Pinto, Rosaria De Filippi & Antonino Carbone. (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. The Journal of Pathology 221:3, pages 248-263.
Crossref
Crossref
DANIEL BENHARROCH, INBAL EINAV, ALEXANDRA FELDMAN, AMALIA LEVY, SAMUEL ARIAD & JACOB GOPAS. (2010) Apoptosis of Hodgkin–Reed–Sternberg cells in classical Hodgkin lymphoma revisited. APMIS 118:5, pages 339-345.
Crossref
Crossref
Robert Lin, Dan Jones & Sherif Ibrahim. 2010. Neoplastic Hematopathology. Neoplastic Hematopathology
349
366
.
Alfons NavarroTania DiazAntonio Martinez, Anna GayaAina PonsBernat Gel, Carles CodonyGerardo Ferrer, Carmen MartinezEmili MontserratMariano Monzo. (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 114:14, pages 2945-2951.
Crossref
Crossref
Stefan Hohaus, Manuela Giachelia, Giuseppina Massini, Barbara Vannata, Marianna Criscuolo, Maurizio Martini, Francesco D’Alo’, Maria Teresa Voso, Luigi Maria Larocca & Giuseppe Leone. (2009) Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leukemia Research 33:10, pages 1352-1356.
Crossref
Crossref